COVID Vaccine Developer/Manufacturer Announcements

COVID Vaccine Developer/Manufacturer Announcements
[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]


Press Releases
International Respiratory Coalition launches to transform post-pandemic respiratory healthcare
09 September 2021
COVID-19 highlights urgent need for national respiratory strategies to drive improvements in patient outcomes and healthcare system resilience

BioCubaFarma – Cuba
Últimas Noticias – [Website not responding at inquiry; receiving 403-Forbidden]


News – [Website not responding at inquiry]

Clover Biopharmaceuticals – China
Sep 10,2021
Clover Biopharmaceuticals Receives Pharmaceutical Manufacturing Permit from Zhejiang Medical Products Administration to Produce COVID-19 Vaccine
CHENGDU, China, September 9, 2021—Clover Biopharmaceuticals, Ltd. (Clover), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that its wholly-owned subsidiary, Zhejiang Clover Biopharmaceutical, Inc., received a Pharmaceutical Manufacturing Permit from the Zhejiang Medical Products Administration for the production of Clover’s protein-based COVID-19 vaccine candidate at its facility in Changxing, Zhejiang province, China (Changxing facility)…


Curevac [Bayer Ag – Germany]
News – No new digest announcements identified


Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

Home – No new digest announcements identified


Press Releases – No new digest announcements identified


Press Releases
September 9, 2021
Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day
:: New development candidate for combination respiratory COVID-19 booster + seasonal flu booster vaccine
:: New pediatric combination development candidate for RSV + hMPV vaccine
:: Interim Phase 1 data from RSV vaccine candidate in older adults significantly boosted neutralizing antibody titers above baseline
:: New infectious disease therapeutic vaccine candidate, to complement Epstein-Barr virus prophylactic vaccine
:: Phase 2 randomized, placebo-controlled study of personalized cancer vaccine fully enrolled; primary endpoint is recurrence free survival at 12 months
:: Company continues to scale with 37 programs in development, including 22 in ongoing clinical studies

September 8, 2021
Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine


Press Releases
Novavax Statement on Takeda Agreement to Provide 150 Million Doses of NVX-CoV2373 to the Government of Japan
Sep 10, 2021

Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
Sep 10, 2021
— First participants enrolled in Phase 1 clinical trial of combination NanoFlu™/NVX-CoV2373 vaccine with Matrix-M™ adjuvant
— Phase 1/2 study will evaluate immunogenicity and safety


Recent Press Releases – No new digest announcements identified


Sanofi Pasteur
Press Releases – No new digest announcements identified


Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified


News – [Website not responding at inquiry]


Press Releases
New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant
Study findings demonstrate that a booster dose of inactivated COVID-19 vaccine produces a highly sifted, humoral immune response via a sustained evolution of antibodies, able to effectively neutralize SARS-CoV-2 variants of concern.

SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents
BEIJING, China, Sep 9, 2021 – SINOVAC Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac®, an innovative, inactivated coronavirus vaccine developed by SINOVAC Life Sciences Co., Ltd. (“SINOVAC”), a subsidiary of the Company, received approval from the Public Health Institute of Chile (“ISP”) for emergency use for children and adolescents aged between 6 and 17…


Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]



Press releases for media – No new digest announcements identified


SK Biosciences
Press releases – No new digest announcements identified